255 related articles for article (PubMed ID: 22743296)
1. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.
Gautschi O; Pauli C; Strobel K; Hirschmann A; Printzen G; Aebi S; Diebold J
J Thorac Oncol; 2012 Oct; 7(10):e23-4. PubMed ID: 22743296
[No Abstract] [Full Text] [Related]
2. Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.
Myall NJ; Neal JW; Cho-Phan CD; Zhou LY; Stehr H; Zhou L; Diehn M; Wakelee HA
Clin Lung Cancer; 2016 Mar; 17(2):e17-21. PubMed ID: 26776917
[No Abstract] [Full Text] [Related]
3. Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.
Gautschi O; Peters S; Zoete V; Aebersold-Keller F; Strobel K; Schwizer B; Hirschmann A; Michielin O; Diebold J
Lung Cancer; 2013 Nov; 82(2):365-7. PubMed ID: 24035431
[TBL] [Abstract][Full Text] [Related]
4. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
Robinson SD; O'Shaughnessy JA; Cowey CL; Konduri K
Lung Cancer; 2014 Aug; 85(2):326-30. PubMed ID: 24888229
[TBL] [Abstract][Full Text] [Related]
5. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.
Schmid S; Siano M; Joerger M; Rodriguez R; Müller J; Früh M
Lung Cancer; 2015 Jan; 87(1):85-7. PubMed ID: 25466451
[TBL] [Abstract][Full Text] [Related]
6. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.
Peters S; Michielin O; Zimmermann S
J Clin Oncol; 2013 Jul; 31(20):e341-4. PubMed ID: 23733758
[No Abstract] [Full Text] [Related]
7. BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib.
El Karak F; Assi T; Kourie HR; El Rassy E; Chebib R; Ghor M; Tabchi S
Int J Clin Exp Pathol; 2015; 8(3):3294-8. PubMed ID: 26045855
[TBL] [Abstract][Full Text] [Related]
8. Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.
Starz H; Gutschi M; Welzel J; Haas C
J Dtsch Dermatol Ges; 2014 Feb; 12(2):151-4. PubMed ID: 24238398
[No Abstract] [Full Text] [Related]
9. Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.
Charles J; Beani JC; Fiandrino G; Busser B
J Am Acad Dermatol; 2014 Sep; 71(3):e97-9. PubMed ID: 25128147
[No Abstract] [Full Text] [Related]
10. Granuloma Annulare Secondary to Vemurafenib Therapy for Lung Adenocarcinoma.
Jenkinson HA; Siroy AE; Choksi A
J Drugs Dermatol; 2017 Oct; 16(10):1050-1052. PubMed ID: 29036262
[TBL] [Abstract][Full Text] [Related]
11. Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.
Koers K; Francken AB; Haanen JB; Woerdeman LA; van der Hage JA
J Clin Oncol; 2013 Jun; 31(16):e251-3. PubMed ID: 23569313
[No Abstract] [Full Text] [Related]
12. Sustained Response to Vemurafenib in a BRAF
Prager GW; Koperek O; Mayerhoefer ME; Muellauer L; Wrba F; Niederle B; Zielinski CC; Raderer M
Thyroid; 2016 Oct; 26(10):1515-1516. PubMed ID: 27532222
[No Abstract] [Full Text] [Related]
13. Overcoming resistance in a
Schmid T; Buess M
Curr Oncol; 2018 Jun; 25(3):e217-e219. PubMed ID: 29962848
[TBL] [Abstract][Full Text] [Related]
14. Vemurafenib.
Garbe C; Abusaif S; Eigentler TK
Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
[TBL] [Abstract][Full Text] [Related]
15. Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib.
Idbaih A; Mokhtari K; Emile JF; Galanaud D; Belaid H; de Bernard S; Benameur N; Barlog VC; Psimaras D; Donadieu J; Carpentier C; Martin-Duverneuil N; Haroche J; Feuvret L; Zahr N; Delattre JY; Hoang-Xuan K
Neurology; 2014 Oct; 83(16):1478-80. PubMed ID: 25209580
[No Abstract] [Full Text] [Related]
16. Pilomyxoid astrocytoma treated successfully with vemurafenib.
Skrypek M; Foreman N; Guillaume D; Moertel C
Pediatr Blood Cancer; 2014 Nov; 61(11):2099-100. PubMed ID: 24821190
[TBL] [Abstract][Full Text] [Related]
17. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
18. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
[No Abstract] [Full Text] [Related]
19. The histopathology of BRAF-V600E-mutated lung adenocarcinoma.
Yousem SA; Nikiforova M; Nikiforov Y
Am J Surg Pathol; 2008 Sep; 32(9):1317-21. PubMed ID: 18636014
[TBL] [Abstract][Full Text] [Related]
20. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
Keating GM; Lyseng-Williamson KA
Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
